Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pacritinib is a JAK2/IRAK1/CSF1R/FLT3 inhibitor, with an established safety and efficacy profile in the treatment of myeloproliferative neoplasms (myelofibrosis) and of acute GVHD.
Pacritinib s immunomodulatory effects suggest therapeutic benefit for cGVHD, without abrogating the graft-versus-leukemia effect after HSCT.
Start - 20
Ehhh already!
MDT has a reputation as a corporate rapist!
Where they arrive they made scorched earth.
Yes Yes you are right!
Now I sell everything.
BHUHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHA
https://investor.sppirx.com/static-files/065d30ea-22d7-4d12-a37f-6633d06326eb
Pozi pozi or not pozi?
They shoulda...
Good poster!
https://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-announces-data-poster-presentation
The poster titled “High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC)” is being presented by Xiuning Le, M.D., Ph.D., Assistant Professor, The University of Texas MD Anderson Cancer Center on September 12, 2022.
https://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-announces-data-poster-presentation
The poster titled “High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC)” is being presented by Xiuning Le, M.D., Ph.D., Assistant Professor, The University of Texas MD Anderson Cancer Center on September 12, 2022.
AXS-07 reminds me of SPPI and the problems they had with Rolontis (eflapegrastim)!
Same problem but in South Korea.
Tomorrow, after a year, we will know the verdict for SPPI
I ask myself the same question thinking about 7.
IMO It depends if they find partnerships ...
I ask myself the same question thinking about 7.
IMO It depends if they find partnerships ...
Great time to buy!
Cover up it will soon be cold!
let's forget the past!
Livendi it's time to upload IMO!
poor shorts
I see it hard, the sooner you get out the better
CBIO today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 202
Matt Kaplan -- Ladenburg Thalmann and Company -- Analyst
Hi. Good morning, and thanks for taking the questions. I just wanted to dig into AXS-07 a little bit. Where are you with respect to addressing the CMC questions detailed in the CRL? And when do you think you could resubmit the NDA?
Mark Jacobson -- Chief Operating Officer
Hey, Matt. It's Mark. So as you can imagine, the team is doing its work in the background. The CMC team is doing its work following the CRL.
And this morning, we did announce that we've requested and submitted a request for a Type A meeting with FDA. And what we plan to do is once that meeting is held, which we would expect this quarter -- we'd expect it to be held this quarter. Once it's held, then we'll be able to -- we'll be in a position to provide a clear update for our expectations around timing of the resubmission and if there are any nuances about the package or anything like that. But right now, it's status quo in terms of the last update where we think everything is addressable, and that we either have the information on hand or are able to -- in a position to provide it prior to our, or in connection with, our resubmission.
So we'll hopefully have more for you in the not-too-distant future.
what is happening?
why are there no sellers?
is hell about to end? OMG
i can't scoop!
it floats above my line
AXSOME THERAPEUTICS INC - PRO-FORMA CASH AS OF JUNE 30, 2022 OF $243 MILLION
CASH BALANCE AND AVAILABLE LOAN PROCEEDS ARE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO 2025
Axsome Therapeutics Inc (AXSM.O): Jefferies raises target price to $92 from $63
Axsome Therapeutics Inc (AXSM.O): SVB Securities raises target price to $75 from $50
Axsome Therapeutics Inc (AXSM.O): Truist Securities raises target price to $150 from $100
Oh Yes
Thanks!
I’ll sell at $ 77
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=Pacritinib&draw=2&rank=1
it seems to be starting soon
https://clinicaltrials.gov/ct2/show/NCT02891603
what will they do?
1,5 milion shares already!
Why?
already closed!
huh!
added a little!
sinister signals
believe it or not?
the use of the procedure seems aimed at reducing costs quickly!
It should be added but I don't like the management and they could bring it down a lot!
so I wait!
I certainly don't sell it I have 4.5k at $ 3.03
I don't think I'll see them again!
I think the dollar might take it back after the restructuring but I don't like everything I've seen so far!
the use of the procedure seems aimed at reducing costs quickly!
It should be added but I don't like the management and they could bring it down a lot!
so I wait!
I certainly don't sell it I have 4.5k at $ 3.03
I don't think I'll see them again!
I think the dollar might take it back after the restructuring but I don't like everything I've seen so far!
it is not a failure but it looks a lot like this!
I don't understand why they preferred to get to this point!
Why did they choose to finance themselves like this? In the end, it became convenient to leave the business close to the finish line!
I will wait for the renovation to finish!
Cursed be the ones who go short and the assholes who make them easier!
Obseva struggle for survival: the Genevan biopharmaceutical company specializing in the treatment of pathologies related to reproductive medicine and infertility intends to request a moratorium on composition and proceed with collective redundancies.
The company will undergo a profound restructuring, the leaders explain in a press release today. At the origin of the decision are the difficulties encountered by the company in the approval of its Linzagolix preparation, a drug for the treatment of uterine fibroids. The FDA, the American drug control authority, found gaps in the dossier. Obseva intends to provide the missing data and documents, but the process will incur costs. To meet these charges, a license agreement with a Japanese company is therefore revoked and various strategic options relating to the products in the portfolio will be analyzed.
well but here with news like this we could do + 100%!
Perhaps?
Only the vomit comes!
Here the administrators must have dared the inosable!
crazy stuff!
Forget about it
sometimes what it appears to be is not
MDT needs an SP and just happens to be buzzing around here
certainly here it is challenging to succeed
think, soon they will use the same tools, camera and who knows what else
Great you make sense!
The world is strange... think about who buys bitcoin or nft,
me, I like patents!
who wouldn't want to be operated on with just one small hole?
how it runs
Come on, let's take off